Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapy

Journal of Clinical Lipidology

Volumn 5, Issue 2, 2011, Pages 97-104

  Kostis, William J ^a   Moreyra, Abel E ^b   Cheng, Jerry Q ^c   Dobrzynski, Jeanne M ^b   Kostis, John B ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Clinical trials; Legacy effect; Lipid lowering therapy; Mortality; Niacin; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FLUINDOSTATIN; GEMFIBROZIL; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL LITERATURE; META ANALYSIS; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; SYSTEMATIC REVIEW;

HUMANS; HYPOLIPIDEMIC AGENTS; MORTALITY; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 79952550431     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.01.006     Document Type: Article

References (33)

1. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
2. J.R. Kizer, C. Madias, and B. Wilner Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy Am J Cardiol 105 2010 1289 1296
3. P. Amarenco, J. Labreuche, P. Lavallee, and P.J. Touboul Statins in stroke prevention and carotid atherosclerosis: systematic review and up-todate meta-analysis Stroke 35 2004 2902 2909 (Pubitemid 39565192)
4. M. Briel, G.G. Schwartz, and P.L. Thompson Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials JAMA 295 2006 2046 2056 (Pubitemid 44794006)
5. P.M. Ridker, E. Danielson, F.A. Fonseca, and J. Genest Jupiter Study Group. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein N Engl J Med 359 2008 2195 2207
6. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial Results. I Reduction in incidence of coronary heart disease JAMA 251 1984 351 364
7. Brown MS, Goldstein JL. Lowering LDL - not only how low, but how long? Science. 200;311:1721-1723.
8. P.S. Sever, N.R. Poulter, and B. Dahlof ASCOT Investigators: the anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm: extended observations 2 years after trial closure Eur Heart J 29 2008 499 508 (Pubitemid 351264177)
9. W.J. Kostis, L. Thijs, T. Richart, J.B. Kostis, and J.A. Staessen Persistence of mortality reduction after the end of randomized therapy in clinical trials of blood pressure lowering medications Hypertension 56 2010 1060 1068
10. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4s) Lancet 344 1994 1383 1389
11. T.E. Strandberg, K. Pyörälä, T.J. Cook for the 4S Group Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) Lancet 364 2004 771 777 (Pubitemid 39165096)
12. H. Holdaas, B. Fellström, and A.G. Jardine Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators: effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial Lancet 361 2003 2024 2031 (Pubitemid 36695044)
13. H. Holdaas, B. Fellström, and E. Cole Assessment of lescol in renal transplantation (ALERT) study investigators: long-term cardiac outcomes in renal transplant recipient receiving fluvastatin: The Alert Extension Study Am J Transplant 5 2005 2929 2936 (Pubitemid 43923954)
14. P.S. Sever, B. Dahlöf, and N.R. Poulter Ascot Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the anglo-scandinavian cardiac outcomes trial - lipid lowering arm (ascott-lla): a multicentre randomised controlled trial Lancet 361 2003 1149 1158 (Pubitemid 36398384)
15. The Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
16. P.L. Canner, K.G. Berge, and N.K. Wenger Fifteen year mortality in coronary drug project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255 (Pubitemid 17208898)
17. The Lipid Research Clinics Investigators The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up Arch Intern Med 152 1992 1399 1410
18. M.H. Frick, O. Elo, and K. Haapa Helsinki Heart Study. Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia N Engl J Med 317 1987 1237 1245
19. L. Tenkanen, M. Manttari, P.T. Kovanen, H. Virkkunen, and V. Manninen Gemfibrozil in the treatment of dyslipidemia. An 18-year mortality follow-up of the Helsinki heart study Arch Intern Med 166 2006 743 748
20. The Long-Term Intervention With Pravastatin in Ischaemic Disease (Lipid) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
21. The Lipid Study Group Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the lipid trial follow-up Lancet 359 2002 1379 1387
22. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
23. I. Ford, H. Murray, and C.J. Packard West Of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study N Engl J Med 357 2007 1477 1486 (Pubitemid 47572633)
24. O.P. Heinonen, J.K. Huttunen, and V. Manninen The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up J Intern Med 235 1994 41 49 (Pubitemid 24192711)
25. S. Duval, and R. Tweedie Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis Biometrics 56 2000 455 463 (Pubitemid 30422636)
26. R. Rosenthal The "file drawer problem" and tolerance for null results Psychol Bull 86 1979 638 641
27. R.G. Orwin A Fail-safe n for effect size in meta-analysis J Educ Stat 8 1983 157 159
28. M. Borenstein, L.V. Hedges, J.P.T. Higgins, and H.R. Rothstein Introduction to Meta-Analysis 2009 John Wiley & Sons Chichester, West Sussex, UK p. 277-292
29. G.G. Schwartz, A.G. Olsson, and M.D. Ezekowitz Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. the miracl study: A randomized controlled trial Jama 285 2001 1711 1718 (Pubitemid 32259905)
30. K.K. Ray, and C.P. Cannon The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes J Am Coll Cardiol 46 2005 1425 1433 (Pubitemid 41446176)
31. J.C. Cohen, E. Boerwindle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
32. J. Chalmers, and M.E. Cooper UKPDS and the legacy effect N Engl J Med 359 2008 1618 1620
33. W.J. Kostis, and J.B. Kostis Age-neutral guidelines for the primary prevention of cardiovascular disease J Clin Hypertens 11 2009 644 645